Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Breast Neoplasms 628Neoplasm Metastasis 38HER2-positive Breast Cancer 33Breast Neoplasms, Male 30Inflammatory Breast Neoplasms 20Brain Neoplasms 18Stomach Neoplasms 16Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Triple Negative Breast Neoplasms 12Colorectal Neoplasms 10Pancreatic Neoplasms 9Endometrial Neoplasms 9Ovarian Neoplasms 8Cardiotoxicity 8Lung Neoplasms 7Esophageal Neoplasms 7Breast Diseases 7Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pathologic Complete Response 5Carcinoma, Ductal, Breast 5Urinary Bladder Neoplasms 4Sarcoma 4HER2-positive Early Breast Cancer 4HER2 Positive Breast Cancer 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Thyroid Neoplasms 3

Interventions

Trastuzumab 3pyrotinib 2pertuzumab 2Fulvestrant 2tucatinib 1palbociclib 1disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Docetaxel 1Capecitabine 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × Trastuzumab × Breast × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT04385563 2020-05-13

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
338 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡